InsomniaNCT07827677
The Effect of Different rTMS Interventions on Acute Experimental Muscular Pain in Individuals Comorbid With Insomnia
A study testing Repetitive transcranial magnetic stimulation (rTMS) on L M1 and Repetitive transcranial magnetic stimulation (rTMS) on R DLPFC in people with Insomnia and Healthy Adult, run by The Hong Kong Polytechnic University at 1 site in Hong Kong.
Trial summary
Insomnia exacerbates pain sensitivity and impairs physiological recovery from acute musculoskeletal pain. Repetitive transcranial magnetic stimulation (rTMS) has emerged as a promising non-invasive neuromodulation intervention to alleviate pain and modulate central sensory processing. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Insomnia, Healthy Adult, Exercise Induced Muscle Damage
- What is being tested?
- Repetitive transcranial magnetic stimulation (rTMS) on L M1 and Repetitive transcranial magnetic stimulation (rTMS) on R DLPFC
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 30 participants
- Where
- 1 siteHong Kong
- Study dates
- 31 Aug 2026to 31 Aug 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Adults aged 18 to 60 years
- Right hand and foot dominant
Who cannot join
- History of any chronic musculoskeletal pain or presence of existing pain during recruitment
- Previous major injuries or surgery involving the lower limbs
- Sleep disorders other than insomnia
- Clinically diagnosed psychiatric disorders
- Conditions that preclude safe rTMS or pain testing (e.g., severe head trauma, intracranial hypertension, implanted ferromagnetic devices, history of epilepsy, skin conditions at stimulation sites)
- Contraindications to vigorous exercise identified through the physical activity readiness questionnaire (PAR-Q)
- Work night shifts or rotating shift schedules
- Pregnant
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Hong Kong1 site, 1 recruiting
- Recruiting
The Hong Kong Polytechnic University
Hong Kong
Leo Guohui Lin, +852 94267004, guohui-leo.lin@connect.polyu.hk
About this study
Official title: The Effect of Different rTMS Intervention on Acute Experimental Muscular Pain in Individuals Comorbid With Insomnia: a Pilot RCT
Insomnia exacerbates pain sensitivity and impairs physiological recovery from acute musculoskeletal pain. Repetitive transcranial magnetic stimulation (rTMS) has emerged as a promising non-invasive neuromodulation intervention to alleviate pain and modulate central sensory processing. However, whether rTMS can effectively mitigate insomnia-induced pain hyperalgesia and accelerate the recovery trajectory of acute musculoskeletal pain remains unclear, as does the optimal neuroanatomical stimulation target.
Building upon an established experimental pain model, this randomized, sham-controlled study aims to evaluate the restorative effects of three distinct rTMS interventions - targeting the left primary motor cortex (L M1), the right dorsolateral prefrontal cortex (R DLPFC), and a sham condition - on individuals experiencing insomnia. Following a standardized eccentric exercise protocol to induce muscle soreness, participants will receive three sessions of the allocated rTMS intervention at 0, 24, and 48 hours post-exercise. Pain sensitivity, recovery dynamics, and quantitative sensory testing (QST) metrics will be continuously monitored across the recovery timeframe.
The findings from this trial will clarify the therapeutic efficacy of rTMS in modulating acute pain under insomnia states and identify the target-specific mechanisms of cortical stimulation, offering evidence-based non-invasive interventions for musculoskeletal pain management.
- Conditions
- Insomnia, Healthy Adult, Exercise Induced Muscle Damage, Pain Sensitivity, Musculoskeletal Pain
- Being tested
- Repetitive transcranial magnetic stimulation (rTMS) on L M1, Repetitive transcranial magnetic stimulation (rTMS) on R DLPFC, Sham repetitive transcranial magnetic stimulation (rTMS)
- Keywords
- Insomnia, Healthy control, Repetitive Transcranial Magnetic Stimulation (rTMS), Quantitative Sensory Testing (QST), Exercise-Induced Muscle Soreness, Neuromodulation
- Medical subject headings
- Sleep Initiation and Maintenance Disorders, Musculoskeletal Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Repetitive transcranial magnetic stimulation (rTMS) on L M1Device
High-frequency stimulation (10 Hz) will be delivered over left M1 at 90% RMT, consisting of 50 pulses per train, a 25-second inter-train interval, and 30 trains per session, yielding a total of 1500 pulses over 15 minutes.
Repetitive transcranial magnetic stimulation (rTMS) on R DLPFCDevice
Low-frequency stimulation (1 Hz) will be applied over right DLPFC-rTMS at 90% RMT, with 150 trains of 10 pulses per session, a 2-second inter-train interval, and a total of 1500 pulses over 30 min.
Sham repetitive transcranial magnetic stimulation (rTMS)Device
Sham stimulation will be administered using identical parameters but delivered via the sham coil, which reproduces the auditory and somatosensory sensations of active rTMS without inducing cortical stimulation.
| Study group | Role | What they receive |
|---|---|---|
| R DLPFC | Experimental | rTMS interventions targeting the right dorsolateral prefrontal cortex (R DLPFC) Receives: Device: Repetitive transcranial magnetic stimulation (rTMS) on R DLPFC |
| L M1 | Active comparator | rTMS interventions targeting the left primary motor cortex (L M1) Receives: Device: Repetitive transcranial magnetic stimulation (rTMS) on L M1 |
| Sham | Sham comparator | sham rTMS stimulation Receives: Device: Sham repetitive transcranial magnetic stimulation (rTMS) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Muscle damage severity: Muscle pain
Muscle pain will be measured using an 11-point NRS, with 0 representing "no pain" and 10 indicating "worst imaginable pain". The Outcome will be recorded at rest, during a reach for the floor with knees straight, and during a validated hamstring provocative manoeuvre, the "taking-off shoe" test.
Measured: Day 0 to Day 14
Muscle damage severity: Muscle soreness
Muscle soreness will be measured by an 7-point Likert scale, with 0= A complete absence of soreness," 1 = "A light soreness in the muscle felt only when touched/a vague ache," 2 = "A moderate soreness felt only when touched/a slight persistent pain," 3 = "A light muscle soreness when walking up and down stairs," 4 = "A light muscle soreness when walking on flat surface," 5 = "A moderate muscle soreness, stiffness, or weakness when walking," 6 = "A severe muscle soreness, stiffness, or weakness that limits my ability to move."
Measured: Day 0 to Day 14
Pain sensitivity: Thermal pain threshold
Thermal thresholds will be measured with a 30 × 30 mm thermode (TSA 2, Medoc Ltd., Ramat Yishai, Israel). The thermode will be placed gently on the skin without causing deformation. Using the method of limits, temperature will increase or decrease at 1℃/second within a 0 - 51℃ range, with a baseline temperature of 32℃. Participants will press the stop button when the thermal sensation first becomes painful. The mean value of five consecutive trials will be used in the analysis.
Measured: Day 7 and Day 9
Pain sensitivity: Mechanical pain threshold
Mechanical pain threshold will be evaluated using standardised weighted pinprick stimulators (MRC System GmbH, Heidelberg, Germany) with a 0.25mm flat contact area. Seven fixed intensities (8 mN - 512 mN) will be applied. The final threshold will be calculated as the geometric mean of the ascending and descending stimulus intensities from five series.
Measured: Day 7 and Day 9
Pain sensitivity: Pressure pain threshold (PPT)
Pressure pain threshold (PPT) will be assessed with a digital pressure algometer (Medoc Ltd., Ramat Yishai, Israel) equipped with a 1 cm2 rubber probe. Pressure will be applied at 30 kPa per second until participants perceive pain. Three trials will be performed, and the mean scores will be calculated to determine the PPT.
Measured: Day 7 and Day 9
Pain sensitivity: Temporal summation of mechanical pain (TSP-M)
The pinprick stimulator will assess TSP-M at 256 mN. Ten stimuli will be delivered at 1-second intervals over a 1 cm2 area. Pain intensity will be rated on an 11-point NRS after the first and the 10th stimuli. If the NRS pain rating remains 0 out of 10 for three consecutive 256 mN stimuli, intensity will be increased to 512 mN, and the trial will be repeated. TSP-M will be calculated as the NRS difference between the first stimulus and the 10th stimulus.
Measured: Day 7 and Day 9
Pain sensitivity: Temporal summation of heat pain (TSP-H)
TSP-H will be measured with a 9 cm2 thermode (TSA 2, Medoc Ltd., Ramat Yishai, Israel). Two sequences of 10 heat pulses at 46 ℃ and 48 ℃ will be delivered with a 5-minute interval. Each pulse has a 0.5 s duration and will be delivered from a 40 ˚C baseline at a 13°C/s ramp rate and 2.5 s interstimulus interval. The participant will rate pain intensity on an 11-point NRS after each stimulus. TSP-H will be defined as the NRS difference between the 10th stimulus and the first stimulus for each temperature.
Measured: Day 7 and Day 9
Pain sensitivity: Conditioned pain modulation (CPM)
CPM will be evaluated using a noxious conditioning stimulus (CS) and a test stimulus (TS). The CS will be contact heat applied to the dominant volar forearm between the distal third of the forearm and the ulnar styloid. Temperature will be set 1.1 °C above the participant's HPT for 120s, starting from 32 ℃ with an 8°C/s ramp using the TSA 2 device (Medoc Ltd., Ramat Yishai, Israel). During the CPM assessment, if participants could not tolerate the CS (i.e., pain intensity over 8 on the11-point NPRS) or if they reported a pain intensity below 4 on the 11-point NPRS, the temperature of the CS will be adjusted to ensure a safe and adequate stimulus intensity. The TS will be applied to the thenar eminence of the non-dominant hand using a pressure algometer (Medoc Ltd., Ramat Yishai, Israel) to determine PPT before and immediately after the CS. The CPM effect will be calculated by subtracting the PPT measured before the CS from the PPT measured after the CS.
Measured: Day 7 and Day 9
Secondary outcomes (15)
Sleep Questionnaires: the Insomnia Severity Index (ISI)
The ISI is a 7-item self-report questionnaire assessing the nature, severity, and impact of insomnia. Each item is rated on a 5-point Likert scale (0 to 4). The total score ranges from 0 to 28, with higher scores indicating greater severity of insomnia.
Measured: Day 0 and Day 7
Sleep Questionnaires: The Pittsburgh Sleep Quality Index (PSQI)
The PSQI is a 19-item self-report questionnaire that evaluates sleep quality and disturbances over a 1-month time interval. It generates seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Each component is scored from 0 to 3. The sum of these seven component scores yields a global PSQI score ranging from 0 to 21, where higher scores indicate poorer sleep quality.
Measured: Day 0 and Day 7
Sleep diary: Total Sleep Time
Assessed using a daily consensus sleep diary. Total Sleep Time is calculated as the total time spent asleep, derived from the total time in bed (bedtime to rise time) minus sleep onset latency and wake after sleep onset. Higher values indicate longer sleep duration.
Measured: Day 0 to Day 14
Sleep diary: Sleep Onset Latency (SOL)
Assessed using a daily consensus sleep diary. Sleep Onset Latency is the estimated time (in minutes) it takes to fall asleep after turning off the lights. Lower values indicate better sleep onset.
Measured: Day 0 to Day 14
Sleep diary: Wake After Sleep Onset (WASO)
Assessed using a daily consensus sleep diary. WASO is calculated as the total duration of wakefulness (in minutes) between initial sleep onset and final awakening, derived from the number of night awakenings multiplied by their average duration. Lower values indicate better sleep continuity.
Measured: Day 0 to Day 14
Sleep diary: Sleep Efficiency (SE)
Assessed using a daily consensus sleep diary. Sleep Efficiency is calculated as the percentage of time in bed spent asleep: [(Total Sleep Time / Total Time in Bed) × 100]. Total Sleep Time is derived from total time in bed (time between bedtime and rise time) minus sleep onset latency and nocturnal wakefulness (calculated from the number and duration of night awakenings). Scores range from 0% to 100%, with higher percentages indicating better sleep quality.
Measured: Day 0 to Day 14
Actigraphy: Total Sleep Time (TST)
Measured objectively using a wrist-worn ActiGraph accelerometer. Sleep Onset Latency is defined as the period of time (in minutes) between the initial bedtime (lights out) and the onset of continuous sleep detected by the algorithm. Lower values indicate faster sleep onset and better sleep initiation.
Measured: Day 0 to Day 14
Actigraphy: Sleep Onset Latency (SOL)
Measured objectively using a wrist-worn ActiGraph accelerometer. Sleep Onset Latency is defined as the period of time (in minutes) between the initial bedtime (lights out) and the onset of continuous sleep detected by the algorithm. Lower values indicate faster sleep onset and better sleep initiation.
Measured: Day 0 to Day 14
Actigraphy: Wake After Sleep Onset (WASO)
Measured objectively using a wrist-worn ActiGraph accelerometer. WASO is defined as the total number of minutes spent awake after initial sleep onset and before final awakening, as determined by epoch-by-epoch movement counts. Lower values indicate better sleep continuity and fewer night awakenings.
Measured: Day 0 to Day 14
Actigraphy: Sleep Efficiency (SE)
Measured objectively using a wrist-worn ActiGraph accelerometer. Sleep Efficiency is calculated as the percentage of time in bed spent asleep: [(Total Sleep Time / Total Time in Bed) × 100]. Values range from 0% to 100%, with higher percentages indicating better sleep quality and efficiency.
Measured: Day 0 to Day 14
Psychological measurement: Depression, Anxiety, and Stress Scale (DASS-21)
Assessed using the 21-item Depression Anxiety Stress Scales (DASS-21). The instrument consists of three 7-item subscales measuring depression, anxiety, and stress. Each item is rated on a 4-point Likert scale ranging from 0 ("did not apply to me at all") to 3 ("applied to me very much or most of the time"). Sum scores for each subscale are calculated and multiplied by 2 to yield total scores ranging from 0 to 42 for each dimension (Depression: 0-42, Anxiety: 0-42, Stress: 0-42), with a total overall score ranging from 0 to 126. Higher scores indicate greater levels of psychological distress/severity.
Measured: Day 0 to Day 14
Psychological measurement: Pain Catastrophizing Scale (PCS)
Assessed using the 13-item Pain Catastrophizing Scale (PCS) to evaluate catastrophic thoughts and feelings associated with pain (comprising rumination, magnification, and helplessness subscales). Each item is rated on a 5-point Likert scale from 0 ("not at all") to 4 ("all the time"). The total score ranges from 0 to 52, with higher scores indicating higher levels of pain catastrophizing.
Measured: Day 0 to Day 14
Psychological measurement: Fear of Pain Questionnaire (FPQ-9)
Assessed using the 9-item short form of the Fear of Pain Questionnaire (FPQ-9) to assess fear of different painful experiences across severe pain, minor pain, and medical pain domains. Each item is rated on a 5-point Likert scale from 1 ("not at all") to 5 ("extreme"). The total score ranges from 9 to 45, with higher scores indicating greater fear of pain.
Measured: Day 0 to Day 14
Psychological measurement: Tampa Scale for Kinesiophobia (TSK-11)
Assessed using the 11-item Tampa Scale for Kinesiophobia (TSK-11) to evaluate fear of movement or (re)injury. Each item is scored on a 4-point Likert scale ranging from 1 ("strongly disagree") to 4 ("strongly agree"). The total score ranges from 11 to 44, with higher scores indicating greater fear of movement/kinesiophobia.
Measured: Day 0 to Day 14
Physical Activity Level: International Physical Activity Questionnaire - Short Form (IPAQ-SF)
Assessed using the 7-item International Physical Activity Questionnaire - Short Form (IPAQ-SF). The questionnaire measures the duration (minutes) and frequency (days) of walking, moderate-intensity activities, and vigorous-intensity activities performed over the last 7 days. Total physical activity volume is calculated as MET-minutes per week (MET-min/week) using standardised MET energy expenditure values: Walking = 3.3 METs, Moderate PA = 4.0 METs, and Vigorous PA = 8.0 METs. The total score is the sum of (METs × minutes × days) across all three domains, with scores starting from 0 and no strict upper limit. Higher scores indicate higher levels of overall physical activity.
Measured: Day 0 to Day 14
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2026
- Study start31 Aug 2026 (estimated)
- Primary completion31 Aug 2027 (estimated)
- Study completion31 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for InsomniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The Hong Kong Polytechnic University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07827677
- Sponsor's protocol ID
- Insomnia-DOMS-rTMS-2026
- Status last verified
- Aug 2026
- First submitted
- 2 Sep 2026
- Last updated
- 18 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Different rTMS Intervention on Acute Experimental Muscular Pain in Individuals Comorbid With Insomnia: a Pilot RCT
- ClinicalTrials.gov ID
- NCT07827677
- Acronym / sponsor ID
- Insomnia-DOMS-rTMS-2026
- Conditions
- Insomnia, Healthy Adult, Exercise Induced Muscle Damage, Pain Sensitivity, Musculoskeletal Pain
- Keywords
- Insomnia, Healthy control, Repetitive Transcranial Magnetic Stimulation (rTMS), Quantitative Sensory Testing (QST), Exercise-Induced Muscle Soreness, Neuromodulation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- The Hong Kong Polytechnic UniversityUniversity, hospital or other
- Study start
- 31 Aug 2026 (estimated)
- Primary completion
- 31 Aug 2027 (estimated)
- Study completion
- 31 Aug 2027 (estimated)
- First posted
- 18 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Insomnia exacerbates pain sensitivity and impairs physiological recovery from acute musculoskeletal pain. Repetitive transcranial magnetic stimulation (rTMS) has emerged as a promising non-invasive neuromodulation intervention to alleviate pain and modulate central sensory processing. However, whether rTMS can effectively mitigate insomnia-induced pain hyperalgesia and accelerate the recovery trajectory of acute musculoskeletal pain remains unclear, as does the optimal neuroanatomical stimulation target.
Building upon an established experimental pain model, this randomized, sham-controlled study aims to evaluate the restorative effects of three distinct rTMS interventions - targeting the left primary motor cortex (L M1), the right dorsolateral prefrontal cortex (R DLPFC), and a sham condition - on individuals experiencing insomnia. Following a standardized eccentric exercise protocol to induce muscle soreness, participants will receive three sessions of the allocated rTMS intervention at 0, 24, and 48 hours post-exercise. Pain sensitivity, recovery dynamics, and quantitative sensory testing (QST) metrics will be continuously monitored across the recovery timeframe.
The findings from this trial will clarify the therapeutic efficacy of rTMS in modulating acute pain under insomnia states and identify the target-specific mechanisms of cortical stimulation, offering evidence-based non-invasive interventions for musculoskeletal pain management.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| R DLPFC | Experimental | Device: Repetitive transcranial magnetic stimulation (rTMS) on R DLPFCrTMS interventions targeting the right dorsolateral prefrontal cortex (R DLPFC) |
| L M1 | Active comparator | Device: Repetitive transcranial magnetic stimulation (rTMS) on L M1rTMS interventions targeting the left primary motor cortex (L M1) |
| Sham | Sham comparator | Device: Sham repetitive transcranial magnetic stimulation (rTMS)sham rTMS stimulation |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Adults aged 18 to 60 years
- Right hand and foot dominant
Key exclusion criteria (8 listed)
- History of any chronic musculoskeletal pain or presence of existing pain during recruitment
- Previous major injuries or surgery involving the lower limbs
- Sleep disorders other than insomnia
- Clinically diagnosed psychiatric disorders
- Conditions that preclude safe rTMS or pain testing (e.g., severe head trauma, intracranial hypertension, implanted ferromagnetic devices, history of epilepsy, skin conditions at stimulation sites)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Repetitive transcranial magnetic stimulation (rTMS) on L M1High-frequency stimulation (10 Hz) will be delivered over left M1 at 90% RMT, consisting of 50 pulses per train, a 25-second inter-train interval, and 30 trains per session, yielding a total of 1500 pulses over 15 minutes. | Device | L M1 |
| Repetitive transcranial magnetic stimulation (rTMS) on R DLPFCLow-frequency stimulation (1 Hz) will be applied over right DLPFC-rTMS at 90% RMT, with 150 trains of 10 pulses per session, a 2-second inter-train interval, and a total of 1500 pulses over 30 min. | Device | R DLPFC |
| Sham repetitive transcranial magnetic stimulation (rTMS)Sham stimulation will be administered using identical parameters but delivered via the sham coil, which reproduces the auditory and somatosensory sensations of active rTMS without inducing cortical stimulation. | Device | Sham |
Primary outcome
Muscle damage severity: Muscle pain
Time frame: Day 0 to Day 14
Muscle pain will be measured using an 11-point NRS, with 0 representing "no pain" and 10 indicating "worst imaginable pain". The Outcome will be recorded at rest, during a reach for the floor with knees straight, and during a validated hamstring provocative manoeuvre, the "taking-off shoe" test.
Muscle damage severity: Muscle soreness
Time frame: Day 0 to Day 14
Muscle soreness will be measured by an 7-point Likert scale, with 0= A complete absence of soreness," 1 = "A light soreness in the muscle felt only when touched/a vague ache," 2 = "A moderate soreness felt only when touched/a slight persistent pain," 3 = "A light muscle soreness when walking up and down stairs," 4 = "A light muscle soreness when walking on flat surface," 5 = "A moderate muscle soreness, stiffness, or weakness when walking," 6 = "A severe muscle soreness, stiffness, or weakness that limits my ability to move."
Pain sensitivity: Thermal pain threshold
Time frame: Day 7 and Day 9
Thermal thresholds will be measured with a 30 × 30 mm thermode (TSA 2, Medoc Ltd., Ramat Yishai, Israel). The thermode will be placed gently on the skin without causing deformation. Using the method of limits, temperature will increase or decrease at 1℃/second within a 0 - 51℃ range, with a baseline temperature of 32℃. Participants will press the stop button when the thermal sensation first becomes painful. The mean value of five consecutive trials will be used in the analysis.
Pain sensitivity: Mechanical pain threshold
Time frame: Day 7 and Day 9
Mechanical pain threshold will be evaluated using standardised weighted pinprick stimulators (MRC System GmbH, Heidelberg, Germany) with a 0.25mm flat contact area. Seven fixed intensities (8 mN - 512 mN) will be applied. The final threshold will be calculated as the geometric mean of the ascending and descending stimulus intensities from five series.
Pain sensitivity: Pressure pain threshold (PPT)
Time frame: Day 7 and Day 9
Pressure pain threshold (PPT) will be assessed with a digital pressure algometer (Medoc Ltd., Ramat Yishai, Israel) equipped with a 1 cm2 rubber probe. Pressure will be applied at 30 kPa per second until participants perceive pain. Three trials will be performed, and the mean scores will be calculated to determine the PPT.
Pain sensitivity: Temporal summation of mechanical pain (TSP-M)
Time frame: Day 7 and Day 9
The pinprick stimulator will assess TSP-M at 256 mN. Ten stimuli will be delivered at 1-second intervals over a 1 cm2 area. Pain intensity will be rated on an 11-point NRS after the first and the 10th stimuli. If the NRS pain rating remains 0 out of 10 for three consecutive 256 mN stimuli, intensity will be increased to 512 mN, and the trial will be repeated. TSP-M will be calculated as the NRS difference between the first stimulus and the 10th stimulus.
Pain sensitivity: Temporal summation of heat pain (TSP-H)
Time frame: Day 7 and Day 9
TSP-H will be measured with a 9 cm2 thermode (TSA 2, Medoc Ltd., Ramat Yishai, Israel). Two sequences of 10 heat pulses at 46 ℃ and 48 ℃ will be delivered with a 5-minute interval. Each pulse has a 0.5 s duration and will be delivered from a 40 ˚C baseline at a 13°C/s ramp rate and 2.5 s interstimulus interval. The participant will rate pain intensity on an 11-point NRS after each stimulus. TSP-H will be defined as the NRS difference between the 10th stimulus and the first stimulus for each temperature.
Pain sensitivity: Conditioned pain modulation (CPM)
Time frame: Day 7 and Day 9
CPM will be evaluated using a noxious conditioning stimulus (CS) and a test stimulus (TS). The CS will be contact heat applied to the dominant volar forearm between the distal third of the forearm and the ulnar styloid. Temperature will be set 1.1 °C above the participant's HPT for 120s, starting from 32 ℃ with an 8°C/s ramp using the TSA 2 device (Medoc Ltd., Ramat Yishai, Israel). During the CPM assessment, if participants could not tolerate the CS (i.e., pain intensity over 8 on the11-point NPRS) or if they reported a pain intensity below 4 on the 11-point NPRS, the temperature of the CS will be adjusted to ensure a safe and adequate stimulus intensity. The TS will be applied to the thenar eminence of the non-dominant hand using a pressure algometer (Medoc Ltd., Ramat Yishai, Israel) to determine PPT before and immediately after the CS. The CPM effect will be calculated by subtracting the PPT measured before the CS from the PPT measured after the CS.
15 secondary outcomes
Sleep Questionnaires: the Insomnia Severity Index (ISI)
Time frame: Day 0 and Day 7
Sleep Questionnaires: The Pittsburgh Sleep Quality Index (PSQI)
Time frame: Day 0 and Day 7
Sleep diary: Total Sleep Time
Time frame: Day 0 to Day 14
Sleep diary: Sleep Onset Latency (SOL)
Time frame: Day 0 to Day 14
Sleep diary: Wake After Sleep Onset (WASO)
Time frame: Day 0 to Day 14
Sleep diary: Sleep Efficiency (SE)
Time frame: Day 0 to Day 14
Actigraphy: Total Sleep Time (TST)
Time frame: Day 0 to Day 14
Actigraphy: Sleep Onset Latency (SOL)
Time frame: Day 0 to Day 14
Actigraphy: Wake After Sleep Onset (WASO)
Time frame: Day 0 to Day 14
Actigraphy: Sleep Efficiency (SE)
Time frame: Day 0 to Day 14
Psychological measurement: Depression, Anxiety, and Stress Scale (DASS-21)
Time frame: Day 0 to Day 14
Psychological measurement: Pain Catastrophizing Scale (PCS)
Time frame: Day 0 to Day 14
Psychological measurement: Fear of Pain Questionnaire (FPQ-9)
Time frame: Day 0 to Day 14
Psychological measurement: Tampa Scale for Kinesiophobia (TSK-11)
Time frame: Day 0 to Day 14
Physical Activity Level: International Physical Activity Questionnaire - Short Form (IPAQ-SF)
Time frame: Day 0 to Day 14
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Insomnia
Recruiting
A Clinical Trial to Evaluate the Effects of Adrenal Adapt on Sleep Quality, Daytime Energy, Stress Resilience, and Cognitive Performance.
Improves Daytime Energy Levels, Reduces Afternoon Energy Crashes and Midday Fatigue
Not yet recruiting
Online Tai Chi Versus Digital CBT-I for Chronic Insomnia
Chronic Insomnia Disorder
Not yet recruiting
Visual and Auditory Stimulation in Intensive Care Patients
Dyspnea, Sleep Quality
Not yet recruiting
Efficacy of MAGNESIO TOTAL on Sleep Quality and Quality of Life in Adults
Sleep Quality, Magnesium Deficiency
Recruiting
The Impact of Overnight Active Temperature Regulation on the Gut Microbiome, Inflammation, and Circadian Rhythm.
Poor Sleep Quality, Gut Microbiome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Repetitive transcranial magnetic stimulation (rTMS) on L M1 and Repetitive transcranial magnetic stimulation (rTMS) on R DLPFC in people with Insomnia and Healthy Adult, run by The Hong Kong Polytechnic University at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Leo Guohui Lin (+852 94267004, guohui-leo.lin@connect.polyu.hk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Muscle damage severity: Muscle pain (time frame: Day 0 to Day 14). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2026.